Caraco Pharma to merge with majority owner Sun

Tuesday, March 1, 2011 08:00 AM

Detroit-based Caraco Pharmaceutical Laboratories has agreed to merge with majority owner Sun Pharmaceutical Industries and Sun Pharma Global, according to Crain’s Detroit Business.

Sun, which owns 75.8% of Caraco's common stock, has agreed to pay all Caraco shareholders a cash payment of $5.25 per share when the deal closes. If shareholders approve, Caraco and Sun will form a private "indirect wholly-owned subsidiary of Sun Pharma incorporated in Michigan." As a privately held company, Caraco's stock would no longer be traded on the NYSE Amex. Last June, the FDA shut down Caraco’s Detroit operations for a variety of manufacturing violations. It has been working the past year to improve quality in the plant. Caraco develops, manufactures, markets and distributes generic pharmaceuticals.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs